Evidence map›Paper›PMID 39165974›Full record

ArticleHeliyon2024

Affinity purification mass spectrometry characterisation of the interactome of receptor tyrosine kinase proline-rich motifs in cancer.

Christopher M Jones, Arndt Rohwedder, Kin Man Suen, Safoura Zahed Mohajerani, Antonio N Calabrese, Sabine Knipp, Mark T Bedford, John E Ladbury

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christopher M JonesDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, UK.
Arndt RohwedderFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.
Kin Man SuenFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.
Safoura Zahed MohajeraniFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.
Antonio N CalabreseFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.
Sabine KnippFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.
Mark T BedfordDepartment of Epigenetics & Molecular Carcinogenesis, University of Texas MD Anderson Cancer Centre, Houston, TX. TX 77230, USA.
John E LadburyFaculty of Biological Sciences, University of Leeds, Leeds, LJ2 9JT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor tyrosine kinase (RTK) overexpression is linked to the development and progression of multiple cancers. RTKs are classically considered to initiate cytoplasmic signalling pathways via ligand-induced tyrosine phosphorylation, however recent evidence points to a second tier of signalling contingent on interactions mediated by the proline-rich motif (PRM) regions of non-activated RTKs. The presence of PRMs on the C-termini of >40 % of all RTKs and the abundance of PRM-binding proteins encoded by the human genome suggests that there is likely to be a large number of previously unexplored interactions which add to the RTK intracellular interactome. Here, we explore the RTK PRM interactome and its potential significance using affinity purification mass spectrometry and in silico enrichment analyses. Peptides comprising PRM-containing C-terminal tail regions of EGFR, FGFR2 and HER2 were used as bait to affinity purify bound proteins from different cancer cell line lysates. 490 unique interactors were identified, amongst which proteins with metabolic, homeostatic and migratory functions were overrepresented. This suggests that PRMs from RTKs may sustain a diverse interactome in cancer cells. Since RTK overexpression is common in cancer, RTK PRM-derived signalling may be an important, but as yet underexplored, contributor to negative cancer outcomes including resistance to kinase inhibitors.

Indexed as

CancerProline-rich motif (PRM)Receptor tyrosine kinase (RTK)SRC homology domain 2 (SH2)SRC homology domain 3 (SH3)

Identifiers

PMID39165974
PMCPMC11334840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.